cvs caremark - Search News

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

MinnPost · 2h

FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%

Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.

Becker's Hospital Review · 1d

FTC finds top 3 PBMs inflated drug prices by $7.3B

The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent passing costs onto patients, employers and healthcare plans, according to a Jan. 14 news release from the agency.

Seeking Alpha on MSN · 1d

FTC finds PBMs excessively marked up prices on specialty drugs

A new report issued by the Federal Trade Commission has found that prescription benefit manager units owned by CVS Health (NYSE:CVS), Cigna (CI) and UnitedHealth Group (UNH) significantly marked up prices for many specialty generic drugs over a six-year period.

Hosted on MSN5h

FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves

CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...

Healthcare Dive7d

CVS successfully converts commercial pharmacy contracts to “cost plus” model

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

Zydus Lifesciences rises 5% on signing agreement with CVS Caremark; Details

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

3hon MSN

UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

Zacks.com on MSN6h

FTC Report Reveals PBM Practices Impacting Competition and Drug Costs

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics